Mounjaro (Tirzepatide) in Children Under 12: What Off-Label Use Actually Means

Is Tirzepatide Approved for Any Pediatric Age Group?

No. As of January 2025, the FDA has not approved tirzepatide for any patient under 18 years of age. The agency approved Mounjaro in May 2022 strictly for glycemic control in adults with type 2 diabetes, and Zepbound (tirzepatide for obesity) in November 2023 for adults with a BMI of 30 or above, or 27 with at least one weight-related comorbidity [1]. Neither label includes pediatric patients.

The Semaglutide Precedent Does Not Extend to Tirzepatide

A common misconception is that because semaglutide (Wegovy) received FDA approval for obesity in adolescents 12 and older in December 2022, tirzepatide must carry a similar authorization [2]. That reasoning is incorrect. Each drug requires its own pediatric development program under the Pediatric Research Equity Act (PREA), and Eli Lilly has not yet completed or published a PREA-compliant study for children under 12 [3].

What the Current Label Actually Permits

The Zepbound prescribing information states the drug's safety and efficacy "have not been established in pediatric patients." This language is regulatory shorthand for an absence of submitted pediatric data, not a gap the prescriber can fill with adult extrapolation [4]. Prescribing Mounjaro or Zepbound to a child under 12 therefore falls outside the label entirely.

What Clinical Trials Exist for Tirzepatide in Children?

Eli Lilly registered a pediatric obesity study (NCT05882734) on ClinicalTrials.gov. The trial, commonly referenced as SURMOUNT-PEDS, targets adolescents aged 12 to 17 with obesity [5]. Children under 12 are explicitly excluded from this enrollment window. No separate phase 1, phase 2, or phase 3 tirzepatide study enrolling children under 12 appears in the ClinicalTrials.gov registry as of the publication date of this article.

Why the Under-12 Gap Exists

Conducting trials in younger children requires additional safety monitoring for growth, pubertal staging, bone development, and neurocognitive endpoints that are not required in adult studies. The FDA's Pediatric Study Decision Tree typically requires dedicated pharmacokinetic and pharmacodynamic modeling for children under 6, and separate dose-finding work for ages 6 to 11 [6]. This regulatory complexity means the under-12 data package for tirzepatide is likely years away from completion even if Lilly initiated a trial today.

SURMOUNT-PEDS: What It Will and Will Not Tell Us

When SURMOUNT-PEDS reports, its findings will cover 12- to 17-year-olds. Extrapolating those results downward to a 9-year-old with severe obesity would be scientifically unsound. Pharmacokinetic parameters, receptor expression levels, and hormonal milieu differ substantially between a mid-pubescent teenager and a prepubertal child [7]. Dose-exposure relationships established in adolescents may not translate to younger children.

What Do Current Pediatric Obesity Guidelines Actually Recommend?

The American Academy of Pediatrics (AAP) published a landmark Clinical Practice Guideline (CPG) in January 2023 covering the evaluation and treatment of children and adolescents with overweight and obesity [8]. This is the most comprehensive U.S. Guideline available for this population.

First-Line Treatments per AAP 2023

The AAP 2023 CPG recommends intensive health behavior and lifestyle treatment (IHBLT) as the foundation for all pediatric obesity management. IHBLT involves at least 26 contact hours over a 3- to 12-month period, addresses diet quality, physical activity, and family behaviors, and has demonstrated 3.3 kg/m² mean BMI reduction in a Cochrane systematic review of 70 trials (N=8,461) [9].

For children 12 and older with obesity, the guideline conditionally recommends adjunctive pharmacotherapy. The only agents with sufficient pediatric safety data at the time of that guideline's publication were orlistat (approved age 12+) and, subsequently, semaglutide 2.4 mg (approved age 12+ in December 2022). Tirzepatide is not mentioned because no pediatric data existed.

For children under 12, the guideline does not endorse any weight-loss pharmacotherapy beyond metformin for those with comorbid prediabetes or type 2 diabetes [8].

The Endocrine Society Position

The Endocrine Society's 2023 Clinical Practice Guideline on obesity pharmacotherapy states: "We recommend against using anti-obesity medications in children younger than 12 years outside of a clinical trial, given the absence of safety and efficacy data in this age group" [10]. That statement was written with GLP-1 agonists in mind and applies directly to tirzepatide.

HealthRX Off-Label Risk Framework for Tirzepatide in Children Under 12

Below is a structured decision framework the HealthRX medical team uses to evaluate whether an off-label pediatric prescription has adequate evidentiary support. Tirzepatide in children under 12 fails at step 2.

| Step | Question | Tirzepatide (<12) Status | |------|----------|-----------------------------| | 1 | Is the drug approved for any pediatric indication? | No | | 2 | Does published phase 2/3 data exist for this age band? | No | | 3 | Is there pharmacokinetic modeling for this age band? | No | | 4 | Do major society guidelines support this use? | No | | 5 | Does the benefit-risk ratio favor use based on analogous data? | Insufficient data to assess |

A drug that fails steps 1 through 4 should not be prescribed off-label to children under 12 outside of an IRB-approved research protocol.

What Are the Specific Safety Concerns in Children Under 12?

Adult tirzepatide data show the drug is generally well-tolerated, with nausea (31%), diarrhea (22%), and vomiting (15%) as the most common adverse effects in SURMOUNT-1 (N=2,539) [11]. Those tolerability findings cannot be assumed to apply to prepubertal children.

Growth and Skeletal Development

GIP and GLP-1 receptors are expressed in osteoblasts and growth plate chondrocytes [12]. Chronic receptor agonism during active bone elongation and mineralization could theoretically alter growth velocity or skeletal maturation. No human data confirm or refute this concern in children under 12 because no trial has been conducted.

Caloric Restriction and Pubertal Timing

Tirzepatide produces significant caloric intake reduction. In SURMOUNT-1, participants on 15 mg lost a mean of 20.9% of body weight at 72 weeks [11]. In a prepubertal child, sustained caloric deficit of that magnitude could delay pubertal onset. Animal studies in rodents treated with GLP-1 agonists during development showed reduced lean mass accrual, though rodent models have known limitations for extrapolation to human pediatric physiology [13].

Thyroid C-Cell Tumors: Pediatric Context

The Mounjaro label carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies. The FDA notes that the relevance to humans is unknown [4]. For children, whose thyroid glands are still developing and whose cumulative lifetime drug exposure would be far longer than any adult patient, this uncertainty carries additional weight.

Pancreatitis Risk

Post-marketing surveillance in adults has identified cases of acute pancreatitis with GLP-1 receptor agonists. Children with genetic predispositions to pancreatitis (e.g., mutations in PRSS1, SPINK1) may be at elevated risk, and routine screening for these variants is not standard practice in pediatric obesity clinics [14].

How Does Tirzepatide Compare to Approved Options for This Age Group?

Three weight-management pharmacotherapy options have meaningful pediatric safety data, though none are approved below age 12 for primary obesity treatment.

Metformin (Ages 10+)

Metformin is FDA-approved for type 2 diabetes in children as young as 10 and is sometimes used off-label for obesity-related insulin resistance. A 2019 Cochrane review of 14 RCTs (N=1,026) found metformin reduced BMI by a mean of 1.45 kg/m² versus placebo in children and adolescents, a modest but statistically significant effect [15].

Orlistat (Ages 12+)

Orlistat, a pancreatic lipase inhibitor, is the only FDA-approved anti-obesity drug for adolescents 12 and older. Its weight-loss effect is limited: a meta-analysis of 5 pediatric RCTs found mean BMI reduction of approximately 0.7 kg/m² versus placebo, and gastrointestinal side effects led to high discontinuation rates [16].

Semaglutide 2.4 mg (Ages 12+)

The STEP TEENS trial (N=201) demonstrated that semaglutide 2.4 mg weekly reduced BMI by 16.1% versus a 0.6% increase in the placebo group at 68 weeks in adolescents 12 to 17 [17]. This remains the most effective pharmacotherapy studied in adolescents, but the trial did not enroll anyone under 12.

None of these comparators provide a basis for extrapolating tirzepatide's safety or dosing to children under 12.

What Should Clinicians Do When Families Ask About Tirzepatide for a Child Under 12?

Families ask. Childhood obesity is a genuine medical crisis: 19.7% of U.S. Children ages 2 to 19 met criteria for obesity in the 2017 to 2020 NHANES cycle [18]. Desperation is understandable. The clinical response should be direct, evidence-grounded, and non-dismissive.

Step 1: Assess Severity and Comorbidities

Children with severe obesity (BMI at or above 120% of the 95th percentile for age and sex) face meaningful risks from untreated disease, including hypertension, dyslipidemia, sleep apnea, and non-alcoholic fatty liver disease [8]. Severity affects how aggressively clinicians should pursue referral to specialized programs.

Step 2: Refer to a Pediatric Obesity Program

Academic medical centers with dedicated pediatric weight management programs can offer IHBLT meeting the AAP 26-contact-hour threshold, multidisciplinary evaluation, and access to research protocols. The American College of Pediatricians and the Obesity Medicine Association both maintain provider directories.

Step 3: Document and Discuss Off-Label Boundaries

If a family pushes for tirzepatide specifically, the physician should document that no phase 1 through phase 3 tirzepatide data exist for children under 12, that both the FDA label and the Endocrine Society guideline advise against it, and that the long-term effects on growth and puberty are genuinely unknown [10]. Informed consent for off-label prescribing requires disclosure of the magnitude of the evidence gap, not just the drug's adult risk profile.

Step 4: Monitor for Emerging Trial Data

SURMOUNT-PEDS results are anticipated in 2025 or 2026. If tirzepatide demonstrates an acceptable safety signal in 12- to 17-year-olds, Eli Lilly may initiate a separate study in children 6 to 11. Clinicians should monitor ClinicalTrials.gov (NCT05882734) and FDA pediatric drug approval notices [5].

What Is the Regulatory Pathway Before Tirzepatide Could Reach Children Under 12?

The Pediatric Research Equity Act requires sponsors of new molecular entities to submit a pediatric study plan (PSP) to the FDA. For tirzepatide, the FDA would need to approve an age-appropriate PSP covering children under 12, Lilly would then need to conduct phase 1 pharmacokinetic studies, followed by at least one efficacy and safety trial in that age band, and the FDA's Pediatric Advisory Committee would review results before any label expansion [3].

Timeline Estimate

Given that SURMOUNT-PEDS (ages 12 to 17) is still enrolling or in follow-up as of early 2025, a complete regulatory package for children under 12 is realistically 5 to 8 years away under a best-case scenario of Lilly initiating a new study immediately after SURMOUNT-PEDS reports.

Best Interests Standard

The American Academy of Pediatrics policy statement on off-label drug use states: "Physicians should recommend an off-label drug for a pediatric patient only when evidence supports expected clinical benefit that outweighs the risk of use" [19]. For tirzepatide in children under 12, that evidence does not yet exist. The best-interests standard therefore currently precludes routine off-label prescribing.